Sumatriptan Succinate
Rank #428 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$19.4M
Total Cost
555,011
Total Claims
$19.4M
Total Cost
24,335
Prescribers
$35
Cost per Claim
29,581
Beneficiaries
643,420
30-Day Fills
$798
Avg Cost/Provider
23
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$19.4M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $19.4M total
Top Prescribers of Sumatriptan Succinate
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Paul Catanzaro | Interventional Pain Management | Saint Louis, MO | 252 | $248K |
| 2 | Gurpreet Padda | Interventional Pain Management | Saint Louis, MO | 168 | $172K |
| 3 | Joseph Peck | Pain Management | Manhattan Beach, CA | 11 | $116K |
| 4 | Aladdin Bolad | Internal Medicine | Alexandria, VA | 21 | $110K |
| 5 | Daniel Schwartz | Neurology | Carmel, NY | 89 | $85K |
| 6 | Noah Rosen | Interventional Pain Management | Great Neck, NY | 172 | $75K |
| 7 | Paul Mathew | Neurology | Cambridge, MA | 139 | $66K |
| 8 | William Burstein | Internal Medicine | Philadelphia, PA | 16 | $61K |
| 9 | Marina Neystat | Neurology | Forest Hills, NY | 23 | $57K |
| 10 | Phillip Mcghee | Family Practice | Oklahoma City, OK | 39 | $56K |
| 11 | Paul Mathew | Neurology | Cambridge, MA | 23 | $55K |
| 12 | Winthrop Risk | Neurology | Cedar Rapids, IA | 220 | $46K |
| 13 | Mary Chiasson | Neurology | Bloomington, MN | 282 | $46K |
| 14 | Casilda Balmaceda | Neurology | New York, NY | 786 | $45K |
| 15 | Javed Iqbal | Neurology | Las Cruces, NM | 11 | $44K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 425 | Clobazam (Clobazam) | $19.8M | 58,877 |
| 426 | Fluorouracil (Fluorouracil) | $19.5M | 220,445 |
| 427 | Ertapenem Sodium (Ertapenem) | $19.4M | 36,784 |
| 428 | Sumatriptan Succinate (Sumatriptan Succinate) | $19.4M | 555,011 |
| 429 | Darbepoetin Alfa In Polysorbat (Aranesp) | $19.3M | 6,889 |
| 430 | Ondansetron Hcl (Ondansetron Hcl) | $19.3M | 1,255,548 |
| 431 | Tasimelteon (Hetlioz) | $19.3M | 763 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology